Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia.
A 7-year-old girl with homozygous familial hypercholesterolaemia and plasma low-density lipoprotein(LDL)-cholesterol levels of 820 mg/dl (21.2 mmol/l) and progressive xanthomata was treated with heparin extracorporeal low-density lipoprotein precipitation (HELP) to lower her plasma LDL. On weekly HELP treatment she maintained her pre-HELP treatment LDL-cholesterol levels at 409 mg/dl (10.6 mmol/l). The long-term HELP treatment was well tolerated and led to regression of her xanthomata. Subsequently, lovastatin [Mevacor; Merck Sharp & Dohme, Westpoint, Pa., USA (20 mg/day)] was added to the regimen, causing a further 20% decrease in her pre-HELP treatment plasma LDL-cholesterol levels. Lovastatin alone did not sufficiently lower her plasma LDL and could not replace the weekly HELP therapy. Our data show that lovastatin is an effective adjunctive therapy for lowering plasma LDL-cholesterol in a homozygous patient, once plasma LDL levels have already been lowered by regular HELP treatment.
Thiery
J
J
Institut für Klinische Chemie, Klinikum Grosshadern der Universität München, Federal Republic of Germany.
Walli
A K
AK
Janning
G
G
Seidel
D
D
D002675:Child, Preschool; D008078:Cholesterol, LDL / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy / Q000628:therapy*; D008148:Lovastatin / Q000494:pharmacology / Q000627:therapeutic use*; D010956:Plasmapheresis / Q000379:methods*; D014973:Xanthomatosis / Q000628:therapy
D008078:Cholesterol, LDL; D008148:Lovastatin